UNSPSC 51241126: Brimonidine

This classification denotes an anti-glaucoma agent and alpha-adrenergic agonist with the molecular formula C11H10BrN5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier E6GNX3HHTE, chemically known as 6-quinoxalinamine, 5-bromo-n-(4,5-dihydro-1h-imidazol-2-yl)- (9ci) but generally known as brimonidine, which bears US NIH Compound Identifier 2435. Brimonidine most often comes in base and tartrate forms.

UNSPSC 51241126 Brimonidine, a Commodity code, covers the procurement of brimonidine tartrate ophthalmic solutions and related formulations used to treat glaucoma and ocular hypertension in state and local healthcare settings. State and local governments purchase brimonidine primarily through public health departments, correctional health services, Veterans Affairs medical facilities, and regional hospital systems serving indigent and safety-net populations. The drug is procured as a line item within larger pharmacy formulary contracts, cooperative purchasing agreements through group purchasing organizations, and competitive bidding processes for pharmaceutical inventory. Procurement typically follows state pharmaceutical board guidelines and federal pricing benchmarks such as the Federal Supply Schedule or state Medicaid reimbursement rates.

The source provided contains no recent state or local contract opportunities tagged to UNSPSC 51241126 Brimonidine. Without posted RFP, RFQ, IFB, or ITN notices identifying specific issuing bodies, response dates, or geographic activity, no representative solicitations or regional concentration patterns can be documented at this time.